Huge surprise: Introgen Therapeutics Inc-INGN receives notice BLA not sufficient to file
Introgen Therapeutics announced that the United States Food and Drug Administration notified the Company that its Biologics License Application for ADVEXIN for the treatment of recurrent, refractory squamous cell carcinoma of the head and neck, submitted on June 30, 2008, was not sufficiently complete and would not be filed at this time. The Company intends to appeal this refuse to file decision and is reviewing the various options available to it.
"Illegitimacy is something we should talk about in terms of not having it."
- Dan Quayle